GlassScriptPhysician profile
Maria Sargent
NPI 1023191392
$6,724.33
in general payments reported to CMS, 2019-2025
36 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,815 · 2022: $1,228 · 2023: $996 · 2024: $1,587 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,227.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,074.72 | 2021-2025 | |
| Novo Nordisk INC | $757.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $517.92 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $489.50 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $456.59 | 2024-2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.80 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $206.57 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.30 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $168.35 | 2022 | |
| Merck Sharp & Dohme LLC | $140.90 | 2021-2024 | Vaxneuvance, Gardasil 9, Verquvo |
| Kowa Pharmaceuticals America, INC. | $125.96 | 2021 | |
| Exact Sciences Corporation | $114.66 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $103.25 | 2021-2022 | |
| Pfizer INC. | $92.03 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $90.30 | 2021 | |
| Phathom Pharmaceuticals, INC. | $89.72 | 2024 | Voquezna |
| Dexcom, INC. | $82.78 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.18 | 2021-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $70.16 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $51.32 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.70 | 2022 | |
| Esperion Therapeutics, INC. | $41.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.19 | 2024-2025 | Abilify Asimtufii |
| Amgen INC. | $37.20 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $33.48 | 2021-2025 | Austedo Xr |
| Daiichi Sankyo INC. | $23.16 | 2022 | |
| Genentech USA, INC. | $19.18 | 2021 | |
| Astellas Pharma US INC | $18.93 | 2021 | |
| Amarin Pharma, INC. | $18.75 | 2022 | |
| Evoke Pharma, INC. | $18.73 | 2025 | |
| Bausch Health US, LLC | $17.87 | 2021 | |
| Abbott Laboratories | $17.48 | 2021 | |
| Sobi, INC | $17.23 | 2023 | |
| Ironwood Pharmaceuticals, INC | $16.14 | 2023 | Linzess |
| Heartflow, INC. | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.